Your browser is no longer supported. Please, upgrade your browser.
Settings
CTRV ContraVir Pharmaceuticals, Inc. daily Stock Chart
CTRV [NASD]
ContraVir Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-86.02 Insider Own8.00% Shs Outstand0.67M Perf Week11.40%
Market Cap5.96M Forward P/E- EPS next Y-0.47 Insider Trans0.00% Shs Float0.48M Perf Month1.52%
Income-16.70M PEG- EPS next Q- Inst Own1.10% Short Float0.31% Perf Quarter-49.20%
Sales- P/S- EPS this Y-84.00% Inst Trans-40.42% Short Ratio0.00 Perf Half Y-70.51%
Book/sh-4.47 P/B- EPS next Y16.10% ROA-179.10% Target Price2.00 Perf Year-91.24%
Cash/sh2.54 P/C3.50 EPS next 5Y- ROE- 52W Range4.80 - 121.10 Perf YTD-54.96%
Dividend- P/FCF- EPS past 5Y16.30% ROI- 52W High-92.66% Beta1.57
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin- 52W Low85.21% ATR2.50
Employees14 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)49.31 Volatility42.15% 31.35%
OptionableNo Debt/Eq- EPS Q/Q56.80% Profit Margin- Rel Volume1.41 Prev Close10.11
ShortableNo LT Debt/Eq- EarningsJun 04 AMC Payout- Avg Volume327.20K Price8.89
Recom3.00 SMA2013.89% SMA50-18.90% SMA200-65.17% Volume460,742 Change-12.07%
Jul-10-18Upgrade Maxim Group Hold → Buy $3
Feb-13-18Downgrade Maxim Group Buy → Hold
May-06-16Initiated Maxim Group Buy $4
Jun-11-19 02:29PM  Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing Benzinga +35.71%
08:30AM  ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B GlobeNewswire
Jun-07-19 02:27PM  Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today InvestorPlace +12.71%
Jun-06-19 11:44AM  ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study Benzinga +41.60%
08:00AM  ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis GlobeNewswire
May-31-19 08:00AM  ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split GlobeNewswire -10.68%
May-06-19 08:00AM  ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision GlobeNewswire
Apr-29-19 08:30AM  ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference GlobeNewswire
Apr-26-19 08:02AM  The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug Benzinga
Apr-25-19 09:02AM  ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering GlobeNewswire -43.35%
Apr-11-19 08:00AM  ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress GlobeNewswire +18.68%
Apr-05-19 02:14PM  Again, Durham pharma loses a drug development partner American City Business Journals
Mar-04-19 02:01PM  ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference GlobeNewswire
Jan-16-19 08:24AM  The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen Benzinga
Jan-15-19 06:25PM  ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders GlobeNewswire
Nov-27-18 04:30PM  ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit GlobeNewswire
Nov-06-18 08:00AM  ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases GlobeNewswire
Oct-30-18 08:05AM  Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors GlobeNewswire
08:00AM  ContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction Study GlobeNewswire
Oct-15-18 08:01AM  Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team GlobeNewswire
Oct-03-18 08:00AM  Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc. GlobeNewswire +9.65%
Sep-18-18 09:00AM  ContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431 GlobeNewswire
Aug-30-18 09:00AM  ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 GlobeNewswire
Aug-07-18 09:00AM  ContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431 GlobeNewswire -8.81%
Aug-06-18 03:30PM  ContraVir Pharmaceuticals Provides an Update to Corporate Objectives GlobeNewswire +12.44%
Jul-23-18 08:00AM  ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431 GlobeNewswire
Jul-10-18 08:35AM  Live Investor Conference & Webinar: NASDAQ and OTC companies to present live on July 12th PR Newswire +5.93%
Jul-05-18 08:35AM  ContraVir Pharmaceuticals to Present at Virtual Investor Conference PR Newswire +5.88%
Jun-29-18 08:00AM  ContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering GlobeNewswire -5.11%
Jun-25-18 08:00AM  ContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human Trial GlobeNewswire
Jun-21-18 08:00AM  ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL GlobeNewswire
Jun-20-18 12:30PM  ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements GlobeNewswire
Jun-18-18 04:01PM  ContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates GlobeNewswire
Jun-14-18 08:23AM  ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States GlobeNewswire +6.90%
Jun-12-18 12:17PM  ContraVir Pharmaceuticals Reminds Investors of Todays Deadline to be a Shareholder of Record GlobeNewswire +7.07%
Jun-05-18 09:00AM  ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering GlobeNewswire
May-31-18 08:00AM  ContraVir Pharmaceuticals Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model GlobeNewswire -5.32%
May-30-18 08:00AM  ContraVir Pharmaceuticals Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study GlobeNewswire
May-29-18 06:00AM  ContraVir Pharmaceuticals to Present at 2018 BIO International Convention GlobeNewswire -6.82%
May-24-18 04:01PM  ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split GlobeNewswire
Apr-12-18 12:46PM  ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress GlobeNewswire
Apr-09-18 06:00AM  ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board GlobeNewswire +6.88%
Apr-03-18 06:00AM  ContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress GlobeNewswire
Feb-22-18 08:00AM  ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population GlobeNewswire +6.96%
Feb-21-18 04:30PM  ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018 GlobeNewswire -5.00%
Feb-12-18 08:27AM  Benzinga Pro's 5 Stocks To Watch Benzinga +16.40%
06:00AM  ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL Leveraging the 505(b)(2) Regulatory Pathway GlobeNewswire
Feb-09-18 06:00AM  ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference GlobeNewswire
Feb-06-18 06:00AM  ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL GlobeNewswire
Feb-05-18 07:00AM  ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Determination GlobeNewswire -8.52%
Jan-23-18 06:00AM  ContraVir Pharmaceuticals to Present at NobleCon14 GlobeNewswire +14.10%
Jan-02-18 06:00AM  ContraVir Pharmaceuticals to Present at Biotech Showcase 2018 GlobeNewswire
Dec-29-17 04:00PM  ContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical Officer GlobeNewswire
Dec-13-17 04:00PM  ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017 GlobeNewswire
Dec-04-17 04:30PM  Is ContraVir Pharmaceuticals Inc (CTRV) Undervalued? Simply Wall St.
Nov-27-17 06:00AM  ContraVir Pharmaceuticals to Make Three Presentations at HEP DART 2017 GlobeNewswire
Nov-06-17 06:00AM  ContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) Program GlobeNewswire
Oct-24-17 06:00AM  ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431 GlobeNewswire -7.69%
Oct-19-17 06:00AM  ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL GlobeNewswire +5.12%
Oct-17-17 06:00AM  ContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of Virology GlobeNewswire
Oct-12-17 06:00AM  ContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure Analyst Day GlobeNewswire +17.47%
Oct-03-17 06:00AM  ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017 GlobeNewswire +11.34%
Sep-30-17 02:47PM  ContraVir Pharmaceuticals Inc (CTRV): How Does It Impact Your Portfolio? Simply Wall St.
Sep-19-17 06:00AM  ContraVir Pharmaceuticals Announces Participation at the Discovery on Target 2017 Conference in Boston GlobeNewswire +5.05%
Sep-11-17 06:00AM  ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex (TXL) in the United States GlobeNewswire +5.99%
Sep-06-17 06:00AM  ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom GlobeNewswire
Sep-05-17 06:00AM  ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 GlobeNewswire
Aug-23-17 07:10AM  Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program ACCESSWIRE
Aug-21-17 08:15AM  3 Stocks to Watch Before the Open ACCESSWIRE
06:00AM  ContraVir Pharmaceuticals Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program GlobeNewswire
Aug-08-17 06:00AM  ContraVir Pharmaceuticals Selected to Present Poster on TXL at the Upcoming AASLD Meeting® 2017 GlobeNewswire
Aug-03-17 06:00AM  ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017 GlobeNewswire
Jun-13-17 06:00AM  ContraVir Pharmaceuticals to Present at 2017 BIO International Convention GlobeNewswire +6.25%
Jun-08-17 06:00AM  ContraVir Pharmaceuticals to Present at 2017 Marcum MicroCap Conference GlobeNewswire
May-04-17 06:00AM  ContraVir to Advance Second-Generation Formulation of Tenofovir Exalidex (TXL) for Treatment of Hepatitis B Virus (HBV) GlobeNewswire
May-01-17 05:01PM  ContraVir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants GlobeNewswire
Apr-25-17 09:00AM  ContraVir Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire
Apr-24-17 04:01PM  ContraVir Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Apr-22-17 09:44AM  Data Enhances Understanding of ContraVirs Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) and CRV431 GlobeNewswire
Apr-20-17 07:00AM  Oral Presentation at EASL Highlights ContraVirs Tenofovir Exalidex (TXL) Antiviral Activity in Hepatitis B (HBV) Patients GlobeNewswire
Apr-11-17 06:00AM  ContraVir to Highlight New Data at EASL The International Liver Congress 2017 in Amsterdam, The Netherlands GlobeNewswire
Apr-04-17 06:00AM  ContraVirs Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg) GlobeNewswire
06:00AM  ContraVirs Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)
Mar-14-17 06:00AM  ContraVir Pharmaceuticals to Present at BIO-Europe Spring 2017 GlobeNewswire
Feb-18-17 01:04PM  CONTRAVIR PHARMACEUTICALS, INC. Financials
Feb-14-17 05:58PM  CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
06:00AM  ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex (TXL) for Treating Hepatitis B PR Newswire
Feb-07-17 06:00AM  ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference PR Newswire
Jan-04-17 10:32AM  CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  ContraVir Pharmaceuticals to Present at Biotech Showcase 2017 PR Newswire
Jan-03-17 04:03PM  CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  ContraVir Awarded Grant from Canada's National Research Council to Advance CRV431 for the Treatment of Hepatitis B PR Newswire
Dec-19-16 11:28AM  CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  ContraVir Expands Phase 2a Trial of Tenofovir Exalidex (Formerly CMX157) to Include Doses above 100 mg PR Newswire
Dec-15-16 10:32AM  CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters
06:00AM  ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors PR Newswire
Dec-09-16 01:01PM  CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-08-16 09:27AM  Biotechs Bolstered on 21st Century Cures Passage
06:00AM  ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B PR Newswire
Nov-14-16 05:49PM  CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was incorporated in 2013 and is headquartered in Edison, New Jersey.